Needham analyst David Saxon maintained a Hold rating on Sight Sciences (SGHT – Research Report) today. The company’s shares closed yesterday at $4.60.
Saxon covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Glaukos, and Azenta. According to TipRanks, Saxon has an average return of 6.2% and a 41.95% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Sight Sciences with a $4.67 average price target.
See the top stocks recommended by analysts >>
SGHT market cap is currently $224.2M and has a P/E ratio of -4.02.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SGHT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sight Sciences (SGHT) Company Description:
Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company’s product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company’s non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.
Read More on SGHT:
- Sight Sciences Releases New Investor Relations Presentation
- Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
- SGHT Earnings this Week: How Will it Perform?
- Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
- Sight Sciences launches Ergo-Series of OMNI Surgical System in Europe
